Antituberculous Therapy-Induced Rare Skin Toxicity: Bullous Pemphigoid

Bullous pemphigoid (BP) is an autoimmune blistering disorder rarely triggered by antituberculous therapy (ATT). A 56-year-old diabetic female developed extensive fluid-filled blisters 72 h after initiating first-line ATT. Skin biopsy and immunofluorescence confirmed BP. ATT was stopped, and treatment with systemic and topical steroids resulted in clinical improvement. Although ATT is known for a wide range of adverse effects, BP is an extremely rare but serious dermatologic toxicity. Early identification and withdrawal of the offending drug are crucial.